{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ADMET", "QSAR", "VEGFR2", "dynamics simulation", "inhibitors.", "molecular docking", "tyrosine kinase"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38299297", "DateCompleted": {"Year": "2024", "Month": "08", "Day": "06"}, "DateRevised": {"Year": "2024", "Month": "08", "Day": "07"}, "Article": {"Language": ["eng"], "ELocationID": ["10.2174/0115734064247526231129080415"], "ArticleDate": [], "Journal": {"ISSN": "1875-6638", "JournalIssue": {"Volume": "20", "Issue": "6", "PubDate": {"Year": "2024"}}, "Title": "Medicinal chemistry (Shariqah (United Arab Emirates))", "ISOAbbreviation": "Med Chem"}, "ArticleTitle": "Structure-Activity Relationship Studies on VEGFR2 Tyrosine Kinase Inhibitors for Identification of Potential Natural Anticancer Compounds.", "Pagination": {"StartPage": "646", "EndPage": "661", "MedlinePgn": "646-661"}, "Abstract": {"AbstractText": ["Over-expression of Vascular Endothelial Growth Factor Receptors (VEGFRs) leads to the hyperactivation of oncogenes. For inhibition of this hyperactivation, the USA Food Drug Administration (FDA) has approved many drugs that show adverse effects, such as hypertension, hypothyroidism, etc. There is a need to discover potent natural compounds that show minimal side effects. In the present study, we have taken structurally diverse known VEGFR2 inhibitors to develop a Quantitative Structure-Activity Relationship (QSAR) model and used this model to predict the inhibitory activity of natural compounds for VEGFR2.", "The QSAR model was developed through the forward stepwise Multiple Linear Regression (MLR) method. A developed QSAR model was used to predict the inhibitory activity of natural compounds. Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) assessment and molecular docking studies were performed. The binding stability of the natural compounds with VEGFR2 was elucidated through Molecular Dynamics (MD) simulation.", "The developed QSAR model against VEGFR2 showed the regression coefficient of the training dataset (r<sup>2</sup>) as 0.81 and the external regression coefficient of the test dataset (r2 test) 0.71. Descriptors, viz., electro-topological state of potential hydrogen bonds (maxHBint2, nHBint6), atom types (minssNH), maximum topological distance matrix (SpMAD_Dt), and 2D autocorrelation (ATSC7v), have been identified. Using this model, 14 natural compounds have been selected that have shown inhibitory activity for VEGFR2, of which six natural compounds have been found to possess a strong binding affinity with VEGFR2. In MD simulation, four complexes have shown binding stability up to 50ns.", "The developed QSAR model has identified 5 conserved activity-inducing physiochemical properties, which have been found to be correlated with the anticancer activity of the nonidentical ligand molecules bound with the VEGFR2 kinase. Lavendustin_A, 3'-O-acetylhamaudol, and arctigenin have been obtained as possible lead natural compounds against the VEGFR2 kinase."], "CopyrightInformation": "Copyright\u00a9 Bentham Science Publishers; For any queries, please email at epub@benthamscience.net."}, "AuthorList": [{"Identifier": ["0000-0003-0107-7539"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Plant Biotechnology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, P.O.- CIMAP, Kukrail Picnic Spot Road, Lucknow 226015 (Uttar Pradesh), India."}, {"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India."}], "LastName": "Verma", "ForeName": "Meenakshi", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Technology Dissemination & Computational Biology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, P.O.- CIMAP, Kukrail Picnic Spot Road, Lucknow, 226015 Uttar Pradesh, India."}], "LastName": "Sarfraz", "ForeName": "Aqib", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Technology Dissemination & Computational Biology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, P.O.- CIMAP, Kukrail Picnic Spot Road, Lucknow, 226015 Uttar Pradesh, India."}], "LastName": "Hasan", "ForeName": "Inamul", "Initials": "I"}, {"Identifier": ["0000-0001-9594-2209"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Plant Biotechnology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, P.O.- CIMAP, Kukrail Picnic Spot Road, Lucknow 226015 (Uttar Pradesh), India."}, {"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India."}], "LastName": "Vasudev", "ForeName": "Prema Gauri", "Initials": "PG"}, {"Identifier": ["0000-0002-2704-5925"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India."}, {"Identifier": [], "Affiliation": "Technology Dissemination & Computational Biology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, P.O.- CIMAP, Kukrail Picnic Spot Road, Lucknow, 226015 Uttar Pradesh, India."}], "LastName": "Khan", "ForeName": "Feroz", "Initials": "F"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Med Chem", "NlmUniqueID": "101240303", "ISSNLinking": "1573-4064"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "KDR protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Tyrosine Kinase Inhibitors"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-2"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Biological Products"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Quantitative Structure-Activity Relationship"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Tyrosine Kinase Inhibitors"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-2"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Cohen P.; Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002,1(4),309-315", "ArticleIdList": ["10.1038/nrd773", "12120282"]}, {"Citation": "Liao J.J.L.; Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007,50(3),409-424", "ArticleIdList": ["10.1021/jm0608107", "17266192"]}, {"Citation": "Holmes K.; Roberts O.L.; Thomas A.M.; Cross M.J.; Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007,19(10),2003-2012", "ArticleIdList": ["10.1016/j.cellsig.2007.05.013", "17658244"]}, {"Citation": "Shibuya M.; Claesson-Welsh L.; Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006,312(5),549-560", "ArticleIdList": ["10.1016/j.yexcr.2005.11.012", "16336962"]}, {"Citation": "Olsson A.K.; Dimberg A.; Kreuger J.; Claesson-Welsh L.; VEGF receptor signalling? in control of vascular function. Nat Rev Mol Cell Biol 2006,7(5),359-371", "ArticleIdList": ["10.1038/nrm1911", "16633338"]}, {"Citation": "Ghosh S.; Sullivan C.A.W.; Zerkowski M.P.; Molinaro A.M.; Rimm D.L.; Camp R.L.; Chung G.G.; High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 2008,39(12),1835-1843", "ArticleIdList": ["10.1016/j.humpath.2008.06.004", "18715621"]}, {"Citation": "Boocock C.A.; Charnock-Jones D.S.; Sharkey A.M.; McLaren J.; Barker P.J.; Wright K.A.; Twentyman P.R.; Smith S.K.; Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995,87(7),506-516", "ArticleIdList": ["10.1093/jnci/87.7.506", "7707437"]}, {"Citation": "Seto T.; Higashiyama M.; Funai H.; Imamura F.; Uematsu K.; Seki N.; Eguchi K.; Yamanaka T.; Ichinose Y.; Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006,53(1),91-96", "ArticleIdList": ["10.1016/j.lungcan.2006.02.009", "16697074"]}, {"Citation": "Paragliola R.M.; Corsello A.; Del Gatto V.; Papi G.; Pontecorvi A.; Corsello S.M.; Lenvatinib for thyroid cancer treatment: Discovery, pre-clinical development and clinical application. Expert Opin Drug Discov 2020,15(1),11-26", "ArticleIdList": ["10.1080/17460441.2020.1674280", "31608696"]}, {"Citation": "Modi S.J.; Kulkarni V.M.; Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, \u2018DFG-out\u2019 inhibitors. J Biomol Struct Dyn 2022,40(12),5712-5727", "ArticleIdList": ["10.1080/07391102.2021.1872417", "33459187"]}, {"Citation": "Wu H.C.; Huang C.T.; Chang D.K.; Anti-angiogenic therapeutic drugs for treatment of human cancer. Int J Cancer 2008,4(2),37-45"}, {"Citation": "Sharma N.; Sharma M.; Rahman Q.I.; Akhtar S.; Muddassir M.; Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: An in silico anti-angiogenic study. J Biomol Struct Dyn 2021,39(8),2806-2823", "ArticleIdList": ["10.1080/07391102.2020.1754916", "32363995"]}, {"Citation": "Lu H.; Murtagh J.; Schwartz E.L.; The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol Pharmacol 2006,69(4),1207-1215", "ArticleIdList": ["10.1124/mol.105.019075", "16415178"]}, {"Citation": "Kimura Y.; Sumiyoshi M.; Baba K.; Anti-tumor actions of major component 3\u2032-O-acetylhamaudol of Angelica japonica roots through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation. Cancer Lett 2008,265(1),84-97", "ArticleIdList": ["10.1016/j.canlet.2008.02.009", "18358599"]}, {"Citation": "Shen S.; Xu X.; Liu Z.; Liu J.; Hu L.; Synthesis and structure\u2013activity relationships of boswellic acid derivatives as potent VEGFR-2 inhibitors. Bioorg Med Chem 2015,23(9),1982-1993", "ArticleIdList": ["10.1016/j.bmc.2015.03.022", "25819335"]}, {"Citation": "Lu K.; Basu S.; The natural compound chebulagic acid inhibits vascular endothelial growth factor A mediated regulation of endothelial cell functions. Sci Rep 2015,5(1),9642", "ArticleIdList": ["10.1038/srep09642", "25859636"]}, {"Citation": "Wilson G.L.; Lill M.A.; Integrating structure-based and ligand-based approaches for computational drug design. Future Med Chem 2011,3(6),735-750", "ArticleIdList": ["10.4155/fmc.11.18", "21554079"]}, {"Citation": "Hoi P.M.; Li S.; Vong C.T.; Tseng H.H.L.; Kwan Y.W.; Lee S.M.Y.; Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors. Methods 2015,71,85-91", "ArticleIdList": ["10.1016/j.ymeth.2014.09.004", "25239735"]}, {"Citation": "Sangande F.; Julianti E.; Tjahjono D.H.; Ligand-based pharmacophore modeling, molecular docking, and molecular dynamic studies of dual tyrosine kinase inhibitor of EGFR and VEGFR2. Int J Mol Sci 2020,21(20),7779", "ArticleIdList": ["10.3390/ijms21207779", "33096664"]}, {"Citation": "Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J.; Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3\u201325. 1. Adv Drug Deliv Rev 2001,46(1-3),3-26", "ArticleIdList": ["10.1016/S0169-409X(00)00129-0", "11259830"]}, {"Citation": "Burley S.K.; Bhikadiya C.; Bi C.; Bittrich S.; Chen L.; Crichlow G.V.; Christie C.H.; Dalenberg K.; Di Costanzo L.; Duarte J.M.; Dutta S.; Feng Z.; Ganesan S.; Goodsell D.S.; Ghosh S.; Green R.K.; Guranovi\u0107 V.; Guzenko D.; Hudson B.P.; Lawson C.L.; Liang Y.; Lowe R.; Namkoong H.; Peisach E.; Persikova I.; Randle C.; Rose A.; Rose Y.; Sali A.; Segura J.; Sekharan M.; Shao C.; Tao Y.P.; Voigt M.; Westbrook J.D.; Young J.Y.; Zardecki C.; Zhuravleva M.; RCSB Protein Data Bank: Powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Res 2021,49(D1),D437-D451", "ArticleIdList": ["10.1093/nar/gkaa1038", "33211854"]}, {"Citation": "Gaulton A.; Hersey A.; Nowotka M.; Bento A.P.; Chambers J.; Mendez D.; Mutowo P.; Atkinson F.; Bellis L.J.; Cibri\u00e1n-Uhalte E.; Davies M.; Dedman N.; Karlsson A.; Magari\u00f1os M.P.; Overington J.P.; Papadatos G.; Smit I.; Leach A.R.; The ChEMBL database in 2017. Nucleic Acids Res 2017,45(D1),D945-D954", "ArticleIdList": ["10.1093/nar/gkw1074", "27899562"]}, {"Citation": "Ibrahim M.T.; Uzairu A.; Uba S.; Shallangwa G.A.; Quantitative structure-activity relationship, molecular docking, drug-likeness, and pharmacokinetic studies of some non-small cell lung cancer therapeutic agents. Beni Suef Univ J Basic Appl Sci 2020,9(1),1-4"}, {"Citation": "Yap C.W.; PaDEL\u2010descriptor: An open source software to calculate molecular descriptors and fingerprints. J Comput Chem 2011,32(7),1466-1474", "ArticleIdList": ["10.1002/jcc.21707", "21425294"]}, {"Citation": "Yadav D.K.; Khan F.; QSAR, docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase\u2010I. J. Chemom 2013,27(1-2),21-33"}, {"Citation": "Duchowicz P.; Castro E.; Partial order theory applied to QSPR-QSAR studies. Comb Chem High Throughput Screen 2008,11(10),783-793", "ArticleIdList": ["10.2174/138620708786734316", "19075600"]}, {"Citation": "Yadav D.; Dhawan S.; Chauhan A.; Qidwai T.; Sharma P.; Bhakuni R.; Dhawan O.; Khan F.; QSAR and docking based semi-synthesis and in vivo evaluation of artemisinin derivatives for antimalarial activity. Curr Drug Targets 2014,15(8),753-761", "ArticleIdList": ["10.2174/1389450115666140630102711", "24975562"]}, {"Citation": "Dudek A.; Arodz T.; G\u00e1lvez J.; Computational methods in developing quantitative structure-activity relationships (QSAR): A review. Comb Chem High Throughput Screen 2006,9(3),213-228", "ArticleIdList": ["10.2174/138620706776055539", "16533155"]}, {"Citation": "Kumer A.; Chakma U.; Chandro A.; Howlader D.; Akash S.; Kobir M.E.; Hossain T.; Matin M.M.; Modified D-glucofuranose computationally screening for inhibitor of breast cancer and triple breast cancer: Chemical descriptor, molecular docking, molecular dynamics and QSAR. J Chil Chem Soc 2022,67(3),5623-5635", "ArticleIdList": ["10.4067/S0717-97072022000305623"]}, {"Citation": "Grisoni F.; Ballabio D.; Todeschini R.; Consonni V.; Molecular descriptors for structure\u2013activity applications: a hands-on approach Computational Toxicology 2018,3-53"}, {"Citation": "Shen M.; LeTiran A.; Xiao Y.; Golbraikh A.; Kohn H.; Tropsha A.; Quantitative structure- activity relationship analysis of functionalized amino acid anticonvulsant agents using k nearest neighbour and simulated annealing PLS methods. J Med Chem 2002,45(13),2811-2823"}, {"Citation": "Veerasamy R.; Rajak H.; Jain A.; Sivadasan S.; Varghese C.P.; Agrawal R.K.; Validation of QSAR models-strategies and importance. Lett Drug Des Discov 2011,3,511-519"}, {"Citation": "Jaiswal M.; Khadikar P.V.; Scozzafava A.; Supuran C.T.; Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2004,14(12),3283-3290", "ArticleIdList": ["10.1016/j.bmcl.2004.03.099", "15149691"]}, {"Citation": "Kim S.; Chen J.; Cheng T.; Gindulyte A.; He J.; He S.; Li Q.; Shoemaker B.A.; Thiessen P.A.; Yu B.; Zaslavsky L.; Zhang J.; Bolton E.E.; PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res 2021,49(D1),D1388-D1395", "ArticleIdList": ["10.1093/nar/gkaa971", "33151290"]}, {"Citation": "Dallakyan S.; Olson A.J.; Small-molecule library screening by docking with PyRx Chemical biology 2015,243-250"}, {"Citation": "Laskowski R.A.; Swindells M.B.; LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011,51(10),2778-2786", "ArticleIdList": ["10.1021/ci200227u", "21919503"]}, {"Citation": "DeLano W.L.; Bromberg S.; PyMOL user\u2019s guide. DeLano Scientific LLC, 629 PyMOL:The PyMOL Molecular Graphic System, Version 1503 Available from: http://www.pymol.org/pymol2004"}, {"Citation": "Abraham M.J.; Murtola T.; Schulz R.; P\u00e1ll S.; Smith J.C.; Hess B.; Lindahl E.; GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015,1-2,19-25", "ArticleIdList": ["10.1016/j.softx.2015.06.001"]}, {"Citation": "Vanommeslaeghe K.; Hatcher E.; Acharya C.; Kundu S.; Zhong S.; Shim J.; Darian E.; Guvench O.; Lopes P.; Vorobyov I.; Mackerell A.D.; CHARMM general force field: A force field for drug\u2010like molecules compatible with the CHARMM all\u2010atom additive biological force fields. J Comput Chem 2010,31(4),671-690", "ArticleIdList": ["10.1002/jcc.21367", "19575467"]}, {"Citation": "Vanommeslaeghe K.; Raman E.P.; MacKerell A.D.; Automation of the CHARMM General Force Field (CGenFF) II: Assignment of bonded parameters and partial atomic charges. J Chem Inf Model 2012,52(12),3155-3168", "ArticleIdList": ["10.1021/ci3003649", "23145473"]}, {"Citation": "Hess B.; Bekker H.; Berendsen H.J.C.; Fraaije J.G.E.M.; LINCS: A linear constraint solver for molecular simulations. J Comput Chem 1997,18(12),1463-1472", "ArticleIdList": ["10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H"]}, {"Citation": "Pandini A.; Schulman H.; Khan S.; Conformational coupling by trans-phosphorylation in calcium calmodulin dependent kinase II. PLOS Comput Biol 2019,15(5),e1006796", "ArticleIdList": ["10.1371/journal.pcbi.1006796", "31150387"]}, {"Citation": "Alam S.; Khan F.; QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase II\u03b1. Drug Des Devel Ther 2014,8,183-195", "ArticleIdList": ["24516330"]}, {"Citation": "Ansari W.A.; Rab S.O.; Saquib M.; Sarfraz A.; Hussain M.K.; Akhtar M.S.; Ahmad I.; Khan M.F.; Pentafuhalol-B, a phlorotannin from brown algae, strongly inhibits the PLK-1 overexpression in cancer cells as revealed by computational analysis. Molecules 2023,28(15),5853", "ArticleIdList": ["10.3390/molecules28155853", "37570823"]}, {"Citation": "Lam T.P.; Nguyen D.N.; Mai T.T.; Tran T.D.; Le M.T.; Huynh P.N.H.; Nguyen D.T.; Tran V.H.; Trinh D.T.T.; Truong P.; Vo C.V.T.; Thai K.M.; Exploration of chalcones as 3-chymotrypsin-like protease (3CLpro) inhibitors of SARS-CoV-2 using computational approaches. Struct Chem 2022,33(5),1707-1725", "ArticleIdList": ["10.1007/s11224-022-02000-3", "35811783"]}, {"Citation": "Singh E.; Jha R.K.; Khan R.J.; Kumar A.; Jain M.; Muthukumaran J.; Singh A.K.; A computational essential dynamics approach to investigate structural influences of ligand binding on Papain like protease from SARS-CoV-2. Comput Biol Chem 2022,99,107721", "ArticleIdList": ["10.1016/j.compbiolchem.2022.107721", "35835027"]}, {"Citation": "Agrahari A.K.; Sneha P.; George Priya Doss C.; Siva R.; Zayed H.; A profound computational study to prioritize the disease-causing mutations in PRPS1 gene. Metab Brain Dis 2018,33(2),589-600", "ArticleIdList": ["10.1007/s11011-017-0121-2", "29047041"]}]}], "History": [{"Year": "2023", "Month": "2", "Day": "3"}, {"Year": "2023", "Month": "10", "Day": "17"}, {"Year": "2023", "Month": "10", "Day": "25"}, {"Year": "2024", "Month": "8", "Day": "6", "Hour": "12", "Minute": "43"}, {"Year": "2024", "Month": "2", "Day": "1", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "2", "Day": "1", "Hour": "4", "Minute": "34"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38299297", "10.2174/0115734064247526231129080415", "MC-EPUB-137790"]}}]}